Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 9/20 | 0.42 |
| ▸ | RARB | P10826 | 9/20 | 0.42 |
| ▸ | RARG | P13631 | 9/20 | 0.42 |
| ▸ | AHR | P35869 | 2/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31347707 | 1.00 | RARA (0.42) | RARARARBRARGAHRGPR55 | |
| SCHEMBL30474198 | 0.73 | CYP1A2 (0.31) | AHRCYP1A2CYP2A6 | |
| SCHEMBL25318358 | 0.73 | AHR (0.31) | AHR | |
| SCHEMBL25323515 | 0.73 | CYP1A2 (0.31) | AHRCYP1A2CYP2A6 | |
| SCHEMBL25402675 | 0.73 | AHR (0.31) | AHR | |
| SCHEMBL31347767 | 0.72 | RARA (0.47) | RARARARBRARGKDM4EMAPT | |
| SCHEMBL25404958 | 0.72 | RARA (0.47) | RARARARBRARGKDM4EMAPT | |
| SCHEMBL31413127 | 0.71 | ABL1 (0.42) | RARARARBRARGKDM4EMAPT | |
| SCHEMBL25321193 | 0.71 | ABL1 (0.42) | RARARARBRARGKDM4EMAPT | |
| SCHEMBL30538815 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| CN-119343339-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-4491625-A1 | BENZO BICYCLIC COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | Guangzhou Unirise Pharmaceutical Co., Ltd. (CN) | 2025-01-15 | — | — | EP | disclosed |
| EP-4469444-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118974037-A | Benzobicyclo compound and preparation method and application thereof | 广州市联瑞制药有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023169436-A1 | BENZO BICYCLIC COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | 广州市联瑞制药有限公司 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023138684-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO , INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | RARA 1601/4885RARB 1663/4885RARG 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.